Universal reference book for medicines
Name of the drug: RIMECOR MV (RIMECOR MV)

Active ingredient: trimetazidine

Type: A drug that improves the metabolism of the myocardium and neurosensory organs under conditions of ischemia

Manufacturer: NIZHFARM (Russia) manufactured by PHARMA START (Ukraine) packed with MAKIZ-PHARMA (Russia)
Composition, form of production and packaging
The tablets of the prolonged action, covered with a film cover of
pink color, round, biconcave, on a cross-section are visible two layers.

1 tab.

trimetazidine dihydrochloride 35 mg

[PRING] mannitol 13.5 mg, microcrystalline cellulose 21 mg, mountain glycolic wax (wax monatin) 39 mg, methyl methacrylate copolymer, trimethylammonioethyl methacrylate chloride and ethyl acrylate [1: 2: 0.1] (Eudragit RS PO) 40 mg, magnesium stearate - 1.5 mg.

Sheath composition: - 8 mg (FD & C lacquer aluminum blue No. 2-0.07%, FD & C lacquer aluminum yellow No. 6 - 0.77%, macrogol (polyethylene glycol) 20.2%, polyvinyl alcohol 40%, lacquer aluminum Ponso 4R 0.24%, talc - 14.8%, titanium dioxide - 23.92%).

10 pieces.
- Packings contour mesh (3) - packs cardboard.
10 pieces.
- packings contour mesh (6) - packs cardboard.
30 pcs.
- Packings contour mesh (1) - packs cardboard.
30 pcs.
- packings contour mesh (2) - packs cardboard.
The tablets of the prolonged action, covered with a film cover of pink color, round, biconcave, on a cross-section are visible two layers.

1 tab.

trimetazidine dihydrochloride 35 mg

[PRING] mannitol 13.5 mg, microcrystalline cellulose 21 mg, mountain glycolic wax (wax monatin) 39 mg, methyl methacrylate copolymer, trimethylammonioethyl methacrylate chloride and ethyl acrylate [1: 2: 0.1] (Eudragit RS PO) 40 mg, magnesium stearate - 1.5 mg.

Sheath composition: - 8 mg (FD & C lacquer aluminum blue No. 2-0.07%, FD & C lacquer aluminum yellow No. 6 - 0.77%, macrogol (polyethylene glycol) 20.2%, polyvinyl alcohol 40%, lacquer aluminum Ponso 4R 0.24%, talc - 14.8%, titanium dioxide - 23.92%).

10 pieces.
- Packings contour mesh (3) - packs cardboard.
10 pieces.
- packings contour mesh (6) - packs cardboard.
30 pcs.
- Packings contour mesh (1) - packs cardboard.
30 pcs.
- packings contour mesh (2) - packs cardboard.
The tablets covered with a covering of pink color, round, biconcave, on a cross-section are visible two layers.

1 tab.

trimetazidine dihydrochloride 35 mg

[PRING] mannitol 13.5 mg, microcrystalline cellulose 21 mg, mountain glycolic wax (wax monatin) 39 mg, methyl methacrylate copolymer, trimethylammonioethyl methacrylate chloride and ethyl acrylate [1: 2: 0.1] (Eudragit RS PO) 40 mg, magnesium stearate - 1.5 mg.

Sheath composition: - 8 mg (FD & C lacquer aluminum blue No. 2-0.07%, FD & C lacquer aluminum yellow No. 6 - 0.77%, macrogol (polyethylene glycol) 20.2%, polyvinyl alcohol 40%, lacquer aluminum Ponso 4R 0.24%, talc - 14.8%, titanium dioxide - 23.92%).

10 pieces.
- Packings contour mesh (3) - packs cardboard.
10 pieces.
- packings contour mesh (6) - packs cardboard.
30 pcs.
- Packings contour mesh (1) - packs cardboard.
30 pcs.
- packings contour mesh (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2012.

PHARMACHOLOGIC EFFECT

Has antihypoxic effect.
Normalizes the energy metabolism of cells that have undergone hypoxia or ischemia. Directly affecting the cardiomyocytes and neurons of the brain, it optimizes their metabolism and function. The cytoprotective effect is caused by an increase in the energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (enhancement of aerobic glycolysis and slowing of oxidation of fatty acids due to selective inhibition of long-chain 3-ketoacyl-CoA-thiolase).
Trimetazidine supports myocardial contractility, prevents the reduction of intracellular adenosine triphosphate (ATP) and creatine phosphate.
Under acidosis, it normalizes the functioning of ion channels of membranes, prevents the accumulation of calcium and sodium ions in cardiomyocytes, normalizes the intracellular concentration of potassium ions.
Reduces intracellular acidosis and increased phosphate content, due to myocardial ischemia and reperfusion.
Prevents the damaging effect of free radicals, preserves the integrity of cell membranes, prevents the activation of neutrophils in the ischemia zone, prolongs the duration of the electrical potential, reduces the yield of creatine phosphokinase from cells and the severity of ischemic myocardial damage.
When angina pectoris reduces the frequency of attacks, reduces the need for nitrates, after 2 weeks of treatment increases exercise tolerance, sharp fluctuations in blood pressure decrease.
Reduces dizziness and noise in the ears of ischemic etiology. In vascular pathology, the eye restores the functional activity of the retina.
PHARMACOKINETICS

After ingestion, trimetazidine is rapidly and almost completely absorbed in the gastrointestinal tract.
Eating does not affect the pharmacokinetic properties of the drug.Bioavailability is 90%. Time to reach the maximum concentration in blood plasma - 3-5 hours.
During the day the concentration in the blood plasma remains at a level exceeding 75% of the concentration, determined 11 hours after taking one tablet of the drug.The equilibrium concentration in blood plasma is reached approximately in 60 hours from the beginning of treatment.
The volume of distribution is 4.8 l / kg, the connection with blood plasma proteins is 16%. Easily penetrates through the histohematological barriers.
It is excreted unchanged, mainly by the kidneys (about 60%).
Half-life is about 7 hours, in patients older than 65 years - about 12 hours. Renal clearance of trimetazidine directly correlates with creatinine clearance (CC), the liver clearance decreases with age.
INDICATIONS

Cardiology:

- IHD - prevention of attacks of stable angina pectoris (as part of combination therapy).

Otorhinolaryngology:

- treatment of cochlear-vestibular disorders of ischemic nature (such as dizziness, tinnitus, hearing impairment).


Ophthalmology:

- chorioretinal vascular disorders with ischemic component.

DOSING MODE

Inside, during a meal.

Rimecor MB is used for 1 tablet 2 times a day (morning and evening).

If you miss one dose, the second dose should not double the dose of the drug.

The course of treatment is recommended by a doctor.

SIDE EFFECT

Frequency of side effects: very often (more than 1/10);
often (more than 1/100 and less than 1/10); infrequently (more than 1/1000 and less than 1/100); rarely (more than 1/10000 and less than 1/1000); very rarely (more than 1 / 10,000), including individual messages.
From the digestive system

Often: abdominal pain, diarrhea, indigestion, nausea, vomiting.

From the side of the cardiovascular system

Rarely: orthostatic hypotension, "tides" of blood to the skin of the face.
From the side of the central nervous system Often: dizziness, headache, asthenia.
Very rarely: extrapyramidal disorders (tremor, rigidity, akinesia), reversible after discontinuation of the drug.

From the skin

Often: skin rash, itching, hives.

CONTRAINDICATIONS

- hypersensitivity to the components of the drug;

- severe renal failure (creatinine clearance less than 15 ml / min);

- pronounced violations of the liver function;

- Pregnancy;

- lactation period;

- age under 18 years (efficiency and safety not established).

PREGNANCY AND LACTATION

Studies on animals have not shown teratogenic effects of trimetazidine, however, due to the lack of clinical data on the safety of the drug during pregnancy, the risk of fetal malformations can not be ruled out.
The use of the drug during pregnancy is contraindicated.
It is not known whether trimetazidine is excreted in breast milk.
If you need to use the drug Rimecor MB during lactation it is necessary to interrupt breastfeeding.
APPLICATION FOR FUNCTIONS OF THE LIVER

Contraindicated in severe renal failure (creatinine clearance less than 15 ml / min).

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

Contraindicated in severe violations of liver function.

APPLICATION FOR CHILDREN

Contraindicated for children under 18 years of age (efficacy and safety not established).

SPECIAL INSTRUCTIONS

Rimecor MB is not intended for relief of angina attacks and is not indicated for the initial course of therapy for unstable angina or myocardial infarction, as well as in preparation for hospitalization or in its first days.

In the case of an attack of angina pectoris, the treatment should be reviewed and adapted.
Because of the lack of appropriate clinical data, the use of Rimecor MB is not recommended for patients with renal insufficiency with creatinine clearance less than 15 ml / min, as well as for patients with severe impairment of liver function.
Impact on the ability to drive vehicles and manage mechanisms

It is advisable to use caution when driving vehicles and engaging in other potentially dangerous activities that require increased concentration and speed of psychomotor reactions.

OVERDOSE

Data on overdose cases are limited.
In case of an overdose, symptomatic therapy should be given.
DRUG INTERACTION

There is no information.

TERMS OF RELEASE FROM PHARMACY

On prescription.

TERMS AND CONDITIONS OF STORAGE

At a temperature of 15 В° C to 25 В° C.
Keep out of the reach of children. Shelf life - 2 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!